Skip to content

Vaccine for pneumonia and meningitis essential in India: experts

June 11, 2014
Participants at the ISPPD meeting

Participants at the ISPPD meeting

Scientists and public health experts from around the world who met at Hyderabad agreed there were sufficient data to mull over introducing  PCV, a vaccine for pneumonia and meningitis in India.

The vaccine, scientifically called pneumococcal conjugate vaccine was a crucial topic of discussion at the 9th International Symposium on Pneumococci and Pneumococcal Diseases, ISPPD from March 9th to 13th.

It can prevent infection by the bacterium Streptococcus pneumoniae (which also goes by pneumococcus). The bacterium is one of the leading causes of pneumonia and meningitis, a severe infection of the protective covering of the brain and spinal cord.

It is one of the leading causes of death globally, taking the lives of more than 1 million children less than five years of age annually. More than 20% of the deaths take place here in India. The number of cases of pneumonia that do not result in death, referred to as morbidity, is also cause for great concern.

In India and around the world 1 in 5 children who develop meningitis die and among those who survive, over 30% suffer permanent disabilities such as deafness, seizures, mental and developmental delays.

Based on recent estimates, more 65,000 Indian children died from pneumococcal disease in 2012.  Many more were hospitalized.  Additionally, the burden to families of children with pneumococcal disease is enormous.  Hospitalisations alone have been estimated to cost Rs2000-14000 for pneumonia and more than Rs 50,000 for meningitis.  In addition, such illnesses cause an enormous economic burden to the families since they often have to miss work in order to provide care for these children.

In order to discuss the increasing disease burden caused by the bacterium specially in this part of the world and find solutions to the problem, the ISPPD was held in India. This was the first time that this global meeting focused on understanding pneumococcus and addressing pneumococcal disease was held in Asia.

It brought together around 1,000 experts from more than 70 countries.  The meeting was unique in its focus on scientific research and emphasis on research collaborations.

The important genomic and epidemiologic findings that were discussed at the meeting could lead to improved pneumococcal disease interventions which could benefit not only India, but all countries in this region.

Some of the interesting topics that were discussed included host and environmental factors associated with pneumococcal disease susceptibility and severity, interactions between pneumococcus and other bacteria that colonise the upper respiratory tract, new microbiological and genetic techniques for determining serotypes of pneumococcus and progress in the development of newer generations of vaccines and the immunologic approaches that researchers are exploring.

For countries planning to introduce pneumococcal conjugate vaccine (PCV), two topics were particularly relevant. They were current data on serotype replacement and vaccine impact studies.

More than 100 countries have already introduced PCV. In South Asia, Pakistan and Afghanistan have introduced PCV into their national programmes.  This year, Nepal and Bangladesh will also add PCV to their schedule and a number of other countries will introduce the vaccine by 2016.  These experiences of introduction and consideration of evidence for decision-making were shared at the symposium.  It was also discussed that vaccine impact studies post-introduction will provide continued evidence for evidence-informed decisions.

The meeting takes place every two years in different countries around the world in collaboration with a local partner organisation. This year, ISPPD was hosted by the INCLEN Trust, a consortium of epidemiologists, social scientists, and health care professionals based in Delhi working on a variety of pressing public health concerns.

It is particularly fitting that this historic and important meeting took place at Hyderabad since over one third of the pneumococcal disease burden comes from India or the neighboring countries.

Currently pneumococcal vaccines seem to be the best answer to the problem and this justifies its inclusion in the National Immunization Programme. However, the current cost of the vaccine is prohibitive, and hence we need to explore partnerships that can offer options for subsidizing it to reach the benefit to the marginalised community which need it the most.

 With inputs from Lois Privor-Dumm


From → Uncategorized

  1. Indian studies showed that the incidence of Invasive Pneumococcal Disease was 10.58% in children admitted to hospitals with suspected invasive bacterial diseases, and 24% of all bacterial pneumonia cases were due to S. pneumonia. (Jaiswal N, Singh M, Thumburu KK, Bharti B, Agarwal A, et al. (2014) Burden of Invasive Pneumococcal Disease in Children Aged 1 Month to 12 Years Living in South Asia: A Systematic Review. PLoS ONE 9(5): e96282).

    Of the available vaccines PCV 13 shows 70% coverage of serotypes prevalent in India and PCV-10 shows 65% coverage whereas PCv-7 has very little coverage less than 40% of serotypes.

  2. raaga permalink

    Dear Sir
    I know I am using wrong platform for discussing this point. But there is no proper way I find to convey my problem to you. Sir This is regarding DBT JRF eligibility. Sir my question is dbt allow students to apply for examination thrice after completing there degrees. but sir It is also mentioned that age limit is 28 years. Sir Can’t this possible that dbt allow students to take three attempts whenever person is willing to take till age 28 years. Because the restriction to take dbt within three years after completing degree raising too many difficulties for aspirants. Also Sir We are very happy that you made it possible to take atleast three attempts.Sir I understand that one plea usually given here and there that if somebody is intelligent he or she will qualify within two or three attempts. I would be highly thankful to you if you will take this in consideration.

Please leave a reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: